

This spreadsheet enables self-audit of a medicines formulary for adherence to NICE Technology Appraisals. No copyright is asserted if used for non-commercial purposes within the NHS.

Technology appraisal (TA) Titles are hyperlinks to full guidance	Date of TA Release	Availability of medicine for NHS patients with this medical condition, as indicated by NICE	Adherence of local formulary to NICE					Notes (e.g. rationale, method of making available)	Any additional comments
			Yes (mark 'x' if applicable)	N/A (mark 'x' if applicable)	Date of local decision (DD/MM/YYYY)	Time to implement (days)			
2011-12									
Atrial fibrillation - dabigatran etexilate (TA249)	31/03/2012	Dabigatran – a recommended option for atrial fibrillation patients with risk factors to prevent stroke and embolism.	x		17/04/2012	17	17	Shared care guideline produced. Available second line to patients intolerant to warfarin or with unstable or erratic INR on warfarin.	
Rheumatoid arthritis - tocilizumab (TA247) Update to TA198	29/02/2012	Tocilizumab (with methotrexate) – a recommended option (in the same circumstances as TA198) after other specified treatments have failed or not been tolerated.	x		17/04/2012	0	0	Already on formulary in line with NICE TA198. Recommendations of NICE TA247 noted.	
Diabetes (type 2) - exenatide (prolonged release) (TA248)	29/02/2012	Exenatide prolonged release – a recommended option in combination with oral drugs for selected patients with type 2 diabetes.	x		17/04/2012	48			
Venom anaphylaxis - immunotherapy pharmligen (TA246)	29/02/2012	Pharmligen – a recommended treatment for bee or wasp venom allergy after a severe reaction, or moderate reaction in certain circumstances.		x	17/04/2012	48			
Venous thromboembolism (hip and knee surgery) - apixiban (TA245)	31/01/2012	Apixiban – a recommended option to reduce thromboembolism after knee/hip replacement.	x		17/04/2012	77			
Chronic obstructive pulmonary disease - roflumilast (TA244)	31/01/2012	Roflumilast – only recommended as part of a clinical trial.		x	20/03/2012	49			
Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (TA242) Review of TA150 and part review of TA118	31/01/2012	Cetuximab – not recommended alone or in combination. Bevacizumab – not recommended with fluoropyrimidines. Panitumumab – not recommended.	x		31/01/2012	0	0	TA242 - not recommended	
Follicular lymphoma - rituximab (TA243) Update to TA110	31/01/2012	Rituximab – recommended in combination for first line treatment of stage II-IV disease.	x		31/01/2012	0	0	Use in line with Thames Valley Cancer Network guidelines	
Leukaemia (chronic myeloid) - dasatinib, nilotinib, imatinib (intolerant, resistant) (TA241)	31/01/2012	Dasatinib – not recommended. Nilotinib – recommended for Philadelphia-chromosome-positive CML if standard dose imatinib unsuccessful or unsuitable. Imatinib high dose – not recommended if disease has progressed after standard dose.	x		31/01/2012	0	0	See TA251	
Arthritis (juvenile idiopathic, systemic) - tocilizumab (TA238)	31/12/2011	Tocilizumab – recommended if NSAIDs, steroids and methotrexate have failed.	x		20/03/2012	80	80	Available as part of patient access scheme	
Breast cancer (metastatic) - fulvestrant (TA239)	31/12/2011	Fulvestrant – not recommended post-menopause in oestrogen dependent metastatic disease, or if disease returned/worsened after anti-oestrogens.	x		31/12/2011	0	0	TA239 - not recommended	
Colorectal cancer (metastatic) - panitumumab (terminated appraisal) (TA240)	31/12/2011	Panitumumab – unable to recommend NHS use. TA terminated due to lack of evidence submission.	x		31/12/2011	0	0	TA240 - not recommended	
Macular oedema (diabetic) - ranibizumab (TA237)	30/11/2011	Ranibizumab – not recommend for people with diabetic macular oedema.	x		20/03/2012	0	0	TA237- not recommended	
Osteosarcoma - infliximab (TA235)	31/10/2011	Infliximab – recommended as a treatment for specified children, adolescents and young adults with osteosarcoma.	x		15/11/2011	15			
Acute coronary syndromes - ticagrelor (TA236)	31/10/2011	Ticagrelor – recommended combined with low-dose aspirin for up to a year as a treatment for specified people with acute coronary syndromes.	x		15/11/2011	15	15	Available as an option and used in line with NICE TA236	
Ankylosing spondylitis - golimumab (TA233)	31/08/2011	Golimumab – a recommended option for severe, active ankylosing spondylitis in the same circumstances as TA143 when NSAIDs unsuccessful.	x		20/09/2011	20		Available as an option, but not currently prescribed	
Rheumatoid arthritis - abatacept (2nd line) (TA234)	31/08/2011	Abatacept – not recommended with methotrexate in moderate to severe RA if DMARDs ineffective.	x		20/09/2011	0	0	TA234 - not recommended	
Macular oedema (retinal vein occlusion) - dexamethasone (TA229)	31/07/2011	Dexamethasone intravitreal implant – recommended for specified people with macular oedema due to retinal vein occlusion.	x		20/09/2011	51		Available, but not currently prescribed as no suitable patient has been identified	
Depression - agomelatine (terminated appraisal) (TA231)	31/07/2011	Agomelatine – unable to recommend NHS use for major depressive episodes. TA terminated due to lack of evidence submission.	x		20/09/2011	0	0	TA231 - not recommended	
Epilepsy (partial) - retigabine (adjuvant) (TA232)	31/07/2011	Retigabine – a recommended adjunctive option for partial onset seizures with or without secondary generalisation in some people with epilepsy.	x		20/09/2011	51		Available as an option, but not currently prescribed	
Multiple myeloma (first line) - bortezomib and thalidomide (TA228)	31/07/2011	Thalidomide – a recommended option for specified people with multiple myeloma. Bortezomib – a recommended option only if thalidomide not tolerated or suitable.	x		20/09/2011	51		Use in line with Thames Valley Cancer Network guidelines	
Myocardial infarction (persistent ST-segment elevation) - bivalirudin (TA230)	31/07/2011	Bivalirudin – recommended as a possible treatment for adults with STEMI having percutaneous coronary intervention.		x	31/07/2011	0	0	PCI not done at Milton Keynes Hospital	
Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (renewed appraisal) (TA232)	30/06/2011	Erlotinib – not recommended as maintenance after platinum-chemotherapy.	x		20/09/2011	0	0	TA227 - not recommended	
Lymphoma (follicular non-Hodgkin's) - rituximab (TA226)	30/06/2011	Rituximab – recommended as a possible treatment to maintain remission.	x		05/07/2011	5		Available to MK patients but issued at Northampton General Hospital	
Rheumatoid arthritis (after failure of previous anti-rheumatic drugs) - golimumab (TA235)	30/06/2011	Golimumab – a recommended option (in the same circumstances as TA130) after other specified treatments have failed or not been tolerated.	x		05/07/2011	5		Available as an option but not currently prescribed.	
Rheumatoid arthritis (methotrexate-naïve) - golimumab (terminated appraisal) (TA224)	30/06/2011	Golimumab – unable to recommend NHS use. TA terminated due to lack of evidence submission.	x		30/06/2011	0	0	TA224 - not recommended	
Peripheral arterial disease - cilostazol, nafidrofuryl oxalate, pentoxifylline and mositol nicotinate (TA223)	31/05/2011	Nafidrofuryl oxalate – a recommended option for intermittent claudication in peripheral arterial disease. Cilostazol, pentoxifylline and mositol nicotinate – not recommended.	x		31/05/2011	0		Already on formulary, prior to NICE TA223	
Thrombocytopenic purpura - romiplostim (TA221)	30/04/2011	Romiplostim – recommended for specified people with chronic, severe, and refractory ITP.	x		05/07/2011	66		Available as part of patient access scheme	
Ovarian cancer (relapsed) - trabectedin (TA222)	30/04/2011	Trabectedin – not recommended with pegylated liposomal doxorubicin for relapsed platinum-sensitive ovarian cancer.	x		05/07/2011	0	0	TA222 - not recommended	
Psoriatic arthritis - golimumab (TA220)	30/04/2011	Golimumab – recommended as a possible treatment after trying other DMARDs in the same circumstances as TA130.	x		05/07/2011	66		Available as an option in line with TA199, but not currently prescribed	
Everolimus for the second-line treatment of advanced renal cell carcinoma (TA219)	30/04/2011	Everolimus – not recommended	x		05/07/2011	0	0	TA219 - not recommended	
			28	3					
			% "Yes"	% "N/A"	-	Average implement time (days)			
Adherence statistics for 2011-12			90%	10%		21			